BioTuesdays

Tag - NASDAQ

Liminal BioSciences

Liminal BioSciences to begin trading on NASDAQ

Common shares of Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) were approved for trading on the Nasdaq Global Market, effective Nov. 18, under the ticker symbol, LMNL. The shares will continue to trade on the Toronto...

Viking Therapeutics Logo

WB starts Viking Therapeutics at OP

William Blair launched coverage of Viking Therapeutics (NASDAQ:VKTX) with an “outperform” rating. The stock closed at $3.97 on April 27. Viking has a differentiated clinical pipeline focusing on modulating hormone...

Ovid Therapeutics

Ladenburg starts Ovid Therapeutics at buy; PT $27

Ladenburg Thalmann initiated coverage of Ovid Therapeutics (NASDAQ:OVID) with a “buy” rating and $27 price target. The stock closed at $10.14 on April 19. Ovid is developing two clinical-stage candidates: OV101, a GABA...

IntriCon Logo

Stifel starts IntriCon at buy; PT $35

Stifel initiated coverage of IntriCon (NASDAQ:IIN) with a “buy” rating and $35 price and also added IntriCon to the Stifel Select List. The stock closed at $19.60 on April 16. “In our opinion, IntriCon is one of the...

Maxim lowers BioLineRx PT to $2 from $3

Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6. BioLineRx, which focuses on...

Obalon Therapeutics

BTIG cuts Obalon Therapeutics PT to $7 from $13

BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is...

Vericel Logo

BTIG ups Vericel PT to $13 from $8

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $13 from $8 after the company beat consensus estimates for the fourth quarter and provided strong guidance for 2018. The stock was quoted at $11.15, up $2.80, in...